Plantible | $30,000,000 | (Nov 19, 2024)
Theranautilus | $1,200,000 | (Nov 19, 2024)
Bluespine | $7,200,000 | (Nov 19, 2024)
InterVene, Inc.
United States
- Redwood City, California
- 08/10/2024
- Series A
- $13,000,000
InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that.
InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.
- Industry Medical Equipment Manufacturing
- Website https://intervene-med.com/
- LinkedIn https://www.linkedin.com/company/intervene-inc./
Zenflow, Inc. | $24,000,000 | (Nov 19, 2024)
Coopah | $1,901,280 | (Nov 19, 2024)
Revisto | $4,000,000 | (Nov 19, 2024)
ChapsVision | $90,000,000 | (Nov 19, 2024)
SuperAnnotate | $36,000,000 | (Nov 19, 2024)
IonKraft | $3,706,797 | (Nov 19, 2024)
ANELLO Photonics | Undisclosed Amount | (Nov 19, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)